bioMérieux 2015 Annual Report

Our performance in 2015 was driven by a strong sales dynamic. Some figures illustrate this trend: with 7.1% organic growth for the year, sales reached nearly €2 billion and robust contributive operating income amounted to €260 million, which represents an increase of nearly 15%.

For 2016 our objectives remain unchanged. For bioMérieux, this means remaining focused on our role as a pioneer in diagnostics and contributing to the fight against infectious diseases.

We are in good shape and well poised today to leverage the numerous advantages the Company enjoys: a balanced product portfolio, effective partnerships to drive innovation, a powerful and versatile production tool and a solid international network.

Division Highlights

• €1,552 million in sales for clinical applications.  For clinical applications, 2015 was an especially constructive year. In keeping its roadmap and true to its ambitions, bioMérieux continued to implement its strategy of fostering innovation and expanding product ranges worldwide.  
• Industrial applications represented 18% of the Company’s sales in 2015. Up by 4.4%, this business witnessed a return to more dynamic growth than during the previous year. At the end of 2015, momentum picked up with a 6% rise in sales during the last quarter compared to the same period in 2014.

Regional Highlights

• The Europe, Middle East, Africa region accounts for 43% of the Company’s total sales. The overall growth in business activity in this region, up by 2.1%, encompasses extremely diverse geographical areas.
• With increasing attention focused on laboratory automation and operational efficiency, and heightened vigilance in the fight against antimicrobial resistance, in 2015, the Americas region recorded fast-paced growth of 16.2% in a favorable market context. Sales in the Americas region amounted to 39% of the Group’s total consolidated sales.
• Accounting for 18% of the Company’s total sales, the Asia Pacific is a region of diversity, with both mature markets – such as Japan and Australia – and emerging markets. The region saw a 3.3% increase in activity over the course of the year. Except in the South Korean market, where instruments sales fell off, all countries in the region are on a growth trajectory.

Sales & Income

• Sales for the year 2015 amounted to €1.965 billion, compared with €1.698 billion in 2014, representing a 7.1% increase at constant exchange rates and scope of consolidation.
• As expected, contributive operating income before nonrecurring items increased in line with organic growth in sales and was supported by positive currency effects. It reached €260 million in 2015 (up by 15% compared to 2014), representing 13.2% of total sales.
• Net income amounted to €110 million, a decline of 18.5% compared to 2014. This decrease was mainly due to the impairment expense on bioTheranostics, which reached €32 million. Net income represented 5.6% of total sales.

Download the Full Report: